Table IV.

MicroRNAs associated with progression-free survival on a cohort-independent or-dependent manner and supporting independent studies.

MicroRNA	P-value	Hazard ratio (95% C.I.)	Relevant literature references
hsa-miR-181c	0.0004	CRN=0: 0.27 (0.16 to 0.47) CRN=1: 0.82 (0.53 to 1.35)	(6, 38)G
hsa-miR-188	<0.0001	2.30 (1.55 to 3.40)	(42)G
hsa-miR-222	0.0814	Male: 1.27 (1.02 to 1.58) Female: 1.65 (1.29 to 2.12)	(6, 37, 38)G
hsa-miR-296	0.0247	RX=0: 1.56 (1.14 to 2.14) RX=1: 3.83 (1.82 to 8.07)	(38, 65)G
	0.0633	CRT=0: 2.04 (1.51 to 2.76) CRT=1: 0.90 (0.39 to 2.10)
ebv-miR-bart7	<0.0001	0.05 (0.01 to 0.15)	(44)O
hsa-miR-486	0.0168	Other: 0.74 (0.44 to 1.25) Caucasian: 1.53 (1.12 to 2.08)	(42)G
hsa-miR-489	0.0041	0.04 (0.00 to 0.36)	(32)O
hsa-miR-512-3p	0.0257	Other: 0.00 (0.00 to 0.04) Caucasian: 0.07 (0.02 to 0.28)	(55, 59)O
hcmv-miR-ul70-3p	0.0004	Male: 0.43 (0.27 to 0.67) Female: 1.13 (0.71 to 1.79)	(33)O
hsa-miR-552	0.0001	0.00 (0.00 to 0.01)	(26)G
hsa-miR-578	<0.0001	0.00 (0.00 to 0.00)	(66)G
hsa-miR-582	0.0003	5.49 (2.17 to 13.88)	(26)G
hsa-miR-584	0.0307	0.22 (0.05 to 0.87)	(26)G
hsa-miR-758	0.0029	CRN=0: 0.77 (0.23 to 2.60) CRN=1: 0.08 (0.03 to 0.21)	(34)O
hsa-miR-93	0.0006	2.63 (1.51 to 4.85)	(31)O
kshv-miR-k12-1	<0.0001	3.19 (1.93 to 5.29)	(27)O
kshv-miR-k12-6-5p	<0.0001	3.70 (1.93 to 7.10)	(67)O
hsa-miR-106b	0.0014	RX=0: 0.12 (0.06 to 0.22) RX=1: 0.55 (0.22 to 1.40)	(43)G
hsa-miR-143	0.0020	Other: 0.30 (0.16 to 0.54) Caucasian: 0.83 (0.61 to 1.12)	(35, 36)O

C.I., Confidence Interval; CRN=1 denotes chemotherapy plus radiation and no targeted therapy, CRN=0 denotes non-CRN therapy; RX=1 denotes radiation therapy alone, RX=0 denotes non-RX therapy; CRT=1 denotes chemotherapy plus radiation and targeted therapy, CRT=0 denotes non-CRT therapy;

^Gglioblastoma multiforme study;

^Ostudy on any other type of cancer; n/a, no association with any type of cancer found in literature.